This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roth, J. Articles by Dobbelstein, M. Search for Related Content PubMed PubMed Citation Articles by Roth, J. Articles by Dobbelstein, M.

Reactivation of Mutant p53 by a One-Hybrid Adaptor Protein¹

Abteilung für Gastroenterologie und Stoffwechsel, Klinikum der Philipps-Universität Marburg, Baldingerstraße, 35043 Marburg [J. R.]; Institut für Virologie, Philipps-Universität Marburg, 35037 Marburg [C. L-B., A. C., K. L., P. K., M. D.]; and Institut für Molekularbiologie und Tumorforschung, Philipps-Universität Marburg, D-35033 Marburg [S. B.], Germany

The most frequent genetic alteration in cancer is a mutation of p53. In most cases, this leads to a sharp increase of the p53 protein levels but abolishes p53’s function as an activator of transcription. To correct this defect, wild-type p53 is being reintroduced into tumor cells through gene therapy vectors, thereby inducing cell death. However, this effect is not necessarily specific for tumor cells. Furthermore, mutant p53 in tumor cells trans-dominantly impairs the function of wild-type p53. As an approach to overcome these obstacles, we have developed an adaptor protein that reactivates mutant p53 rather than stimulating transcription on its own. The DNA binding and tetramerizing portions of the p53-homologue p73 were fused to the oligomerization domain of p53. This chimera binds to the DNA of p53-responsive promoters through the p73-derived portions, and it binds to mutant p53 by the p53-derived oligomerization domain. Through this one-hybrid system, mutant p53 is re-enabled to activate transcription. When the adaptor was expressed in tumor cells that contain mutant p53, expression of p53-responsive genes was activated, and growth was inhibited. No such effects were observed in cells that contain wild-type p53 or no p53 at all. When the adaptor was expressed through an adenovirus vector, tumor cells containing mutant p53 were specifically induced to undergo apoptosis. This strategy can turn mutant p53 into an inhibitor of tumor cell growth and might enable gene therapy to eliminate cancer cells with specificity.

This article has been cited by other articles:

				Y. Tabakin-Fix, I. Azran, Y. Schavinky-Khrapunsky, O. Levy, and M. Aboud Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications Carcinogenesis, April 1, 2006; 27(4): 673 - 681. [Abstract] [Full Text] [PDF]

				K. Kojima, M. Konopleva, I. J. Samudio, M. Shikami, M. Cabreira-Hansen, T. McQueen, V. Ruvolo, T. Tsao, Z. Zeng, L. T. Vassilev, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy Blood, November 1, 2005; 106(9): 3150 - 3159. [Abstract] [Full Text] [PDF]

				U. Hobom and M. Dobbelstein E1B-55-Kilodalton Protein Is Not Required To Block p53-Induced Transcription during Adenovirus Infection J. Virol., July 15, 2004; 78(14): 7685 - 7697. [Abstract] [Full Text] [PDF]